Navigation Links
Off-Label Use of Clotting Drug Soars, Report Finds
Date:4/18/2011

MONDAY, April 18 (HealthDay News) -- Hospitals are using a pricey blood-clotting drug in treating people who do not have hemophilia, a rare disorder in which blood does not clot normally -- even though its use in such patients is potentially risky, according to new research.

Stanford University researchers found that use of the drug, known as recombinant factor 7a, grew by 140 times from use in 125 cases in 2000 to 17,813 in 2008, with off-label uses accounting for most of the increase.

The $10,000-a-dose drug was used in people with hemophilia just 4 percent of the time, according to U.S. hospital statistics from 2000 to 2008. The rest of the time, it was used during heart surgery and to treat medical problems such as trauma and bleeding in the brain. The researchers content that such use puts patients at risk for heart attack and stroke because the drug can boost the risk of blood clots.

"The stakes are high with this one," Dr. Veronica Yank, an instructor in medicine at Stanford and the first author of one of two new studies on the drug, said in a university news release. "Because it's such a powerful clotting agent, it has the potential when used off-label to damage the lives of patients without providing any real benefit."

Yank and her colleagues said that physicians should be more cautious with the drug until there's more research into whether it's appropriate to use in certain cases.

The studies, published April 19 in Annals of Internal Medicine, are accompanied by a commentary from Harvard Medical School researchers, which says the research provides "compelling data about the runaway use, uselessness and risk for this expensive treatment."

The studies were funded by the U.S. Agency for Healthcare Quality and Research after previous research raised concerns that RF7a increased the risk for blood clots. The agency asked for an assessment of five off-label uses of RF7a: heart surgery, intracranial hemorrhage, body and brain trauma, liver transplantation and prostate surgery.

More information

The U.S. National Heart, Lung and Blood Institute has more on hemophilia.

-- Randy Dotinga

SOURCE: Stanford University School of Medicine, news release, April 18, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Hemophilia Drug Used Off-Label Raises Clot Risk
2. Anti-clotting agent does not improve outcomes of patients with severe pneumonia
3. New Anti-Clotting Drug May Work Better After Hip Replacement
4. Extended use of anti-clotting drug helps some bedridden patients
5. Tests to Measure Safety of Anti-Clotting Drugs of Limited Value
6. TBI Therapy and Nutrition: IOM report releases April 20
7. Boston University researchers find most substance-dependent individuals report poor oral health
8. Making temporary changes to brain could speed up learning, study reports
9. Aerobic Exercise May Curb Non-Alcoholic Fatty Liver Disease: Report
10. Brisk Walk Can Boost Blood Flow to the Brain: Report
11. U.S. Reports Drop in AIDS-Related Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Off-Label Use of  Clotting Drug Soars, Report Finds
(Date:5/3/2016)... IN (PRWEB) , ... May 03, 2016 , ... ... benefits advisory organization, announces Benefits Alliance Insurance Services as the latest addition to ... Southern California-based Firm comprised of Partners Wayne Blasman, David Styles, and Paul Vincent. ...
(Date:5/3/2016)... ... May 03, 2016 , ... For the sixth consecutive year, ... Technology (ICT) companies in the annual Branham300 listing. For 23 years, the Branhan300 ... ranked by revenue. , “We are honored to be on the Branham300 ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Dr. Poneh ... on cosmetic dental treatments to both new and existing patients. Cosmetic dentistry allows patients ... for patients who have healthy smiles with some minor or more serious cosmetic flaws. ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... availability of the latest release of DocAve 6 Service Pack (SP) 7, ... organizations migrate to SharePoint 2016 and take advantage of the platform’s latest features ...
(Date:5/3/2016)... , ... May 03, 2016 ... ... of Microsoft secure remote access connectivity solutions, today announced the new SecureAccess ... Microsoft DirectAccess. The new Celestix SecureAccess release will enable organizations to get ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... -- According to market research "Global Magnetic ... Demand Forecast to 2022 - Industry Insights by Architecture ... High Field, Low to Mid Field, and Ultra High ... Vascular, Breast, Pelvic and Abdomen, Cardiac, and Other)" P&S ... was valued at $5,351.7 million in 2015, and it ...
(Date:5/3/2016)... , May 3, 2016 ... Research Report provides a basic overview of the ... post which the surgical mesh report explores into ... Complete report on Surgical Mesh market ... and 98 tables and figures is available at ...
(Date:5/2/2016)... 2016  Deerfield announced today it led the ... Inc. Graybug Vision is an early stage pharmaceutical ... care for ocular diseases including wet age-related macular ... first developed at Johns Hopkins University and has ... Graybug Vision is developing ophthalmology products ...
Breaking Medicine Technology: